MPP signs first COVID-19 licensing deal over MSD’s molnupiravir

UN-backed public health organisation The Medicine Patent Pool (MPP) has entered into a licence agreement with Merck Sharp & Dohme (MSD) and others to increase access to molnupiravir (MK-4482, EIDD-2801)—an investigational oral COVID-19 medicine—for low-and-middle-income countries (LMIC).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

MSD, Pfizer try to stop three Steglatro generics

29 March 2022 Merck Sharp & Dohme and Pfizer have filed three complaints with the Delaware district court to attempt to shut down proposed generics of Steglatro—a diabetes treatment that Pfizer licences to MSD.

Big Pharma

Is big pharma’s antidote to the COVID-19 waiver a viable alternative?

29 July 2021 In May, a consortium of pharmaceutical companies came together to pitch a new plan to help provide more equitable access to COVID-19 vaccines.

Big Pharma

President Xi supports COVID-19 waiver

1 June 2021 President Xi Jingping has announced his support for waiving IP rights for COVID-19 vaccines.